Clinical trials: Chronic Obstruct Airways Disease
Pulmonary Disease, Chronic Obstructive
Tiotropium (18mcg) in Chronic Obstructive Pulmonary Disease (COPD) Patients With a Respiratory Infection
The aim of the study is to investigate whether the early introduction of maintenance bronchodilator therapy during an acute symptomatic episode of the disease shows benefits on the recovery of symptoms.
- Trial name
- NCT01483625
- Testing
- tiotropium
- Where
- 27 sites in United States
- Volunteers
- 140 people
- Sponsor
- Boehringer Ingelheim
Chronic Obstructive Pulmonary Disease (COPD)
Exercise Study in Patient With Chronic Obstructive Pulmonary Disease (0000-036)
To test the effect of the research study drug, inhaled fluticasone on lung function in exercising patients with Chronic Obstructive Pulmonary Disease (COPD).
- Trial name
- NCT00387036
- Testing
- Fluticasone
- Volunteers
- 12 people
- Sponsor
- Merck Sharp & Dohme LLC
Respiratory Failure, Neuromuscular Disease
Autotitrating Versus Standard Non-invasive Ventilation (NIV) in Acute Exacerbation of Respiratory Failure
The aim of the study is to compare the efficacy and tolerance of autotitrating non-invasive ventilation (NIV) versus standard NIV in patients admitted to hospital with acute exacerbation of chronic respiratory failure.
- Conditions
- Respiratory Failure, Neuromuscular Disease, Chest Wall Disorder, Chronic Obstructive Pulmonary Disease
- Trial name
- NCT01174316
- Testing
- AutoVPAP™, VPAPIIIST-A™
- Where
- United Kingdom
- Sponsor
- ResMed
Airway Obstruction
Accurate Recognition of Exacerbation of Chronic Obstructive Pulmonary Disease (COPD)
It has been observed that COPD exacerbations are under-reported in China. One of the reasons for this is Chinese subjects with COPD cannot describe the symptoms of exacerbation mentioned in English.
- Trial name
- NCT03170999
- Testing
- Focus group interview, Draft item set, Candidate item set
- Where
- 3 sites in China
- Volunteers
- 199 people
- Sponsor
- GlaxoSmithKline
COPD
Effect of QVA149 on Exercise Tolerance in Patients With Chronic Obstructive Pulmonary Disease (COPD)
This study assessed the effect of once-daily indacaterol and glycopyrronium bromide (QVA149) on exercise endurance in patients with moderate to severe Chronic Obstructive Pulmonary Disease (COPD).
- Trial name
- BRIGHT (NCT01294787)
- Testing
- indacaterol and glycopyrronium bromide (QVA149), tiotropium
- Where
- 13 sites in Germany, Spain
- Volunteers
- 85 people
- Sponsor
- Novartis Pharmaceuticals
Chronic Obstructive Pulmonary Disease
Observational Non-interventional Study With Spiriva in Chronic Obstructive Pulmonary Disease Patients With Exercise-induced Dyspnoea
This observational non-interventional study is designed to demonstrate the improvement of physical function in COPD patients with exercise-induced dyspnoea on treatment with Spiriva (tiotropium 18 µg capsules) and allows adverse…
- Trial name
- NCT00540163
- Where
- 177 sites in Germany
- Volunteers
- 1,296 people
- Sponsor
- Boehringer Ingelheim
Chronic Obstructive Pulmonary Disease (COPD)
Effects of Mometasone Furoate/Formoterol Combination Versus Formoterol and Mometasone Furoate Alone in Chronic Obstructive Pulmonary Disease (COPD) (Study P04230AM4)(COMPLETED)
This is a randomized, placebo-controlled, parallel-group, multi-site, double-blind study evaluating the efficacy of mometasone furoate/formoterol fumarate (MF/F) metered dose inhaler (MDI) 400/10 mcg twice daily (BID) and MF/F…
- Trial name
- NCT00383721
- Testing
- Mometasone furoate/formoterol (MF/F) combination, Mometasone furoate MDI (MF MDI), Formoterol MDI
- Volunteers
- 1,196 people
- Sponsor
- Organon and Co
Chronic Obstructive Pulmonary Disease
A 12 Week Study of QVA149 Compared to Fluticasone/Salmeterol (Advair) for Treatment of COPD
Study is to show that QVA149 is superior to the standard of care, fluticasone/salmeterol, in patients with moderate to severe airflow limitation.
- Trial name
- NCT01860066
- Testing
- QVA149, fluticasone/salmeterol
- Where
- 31 sites in Argentina, Belgium and 3 more
- Sponsor
- Novartis Pharmaceuticals
Chronic Obstructive Pulmonary Disease - COPD
Safety, Tolerability and Pharmacokinetics of Multiple Ascending Doses of AZD8871 in Healthy Male Japanese Subjects
AZD8871 is a new chemical entity possessing long-acting dual-pharmacology (muscarinic receptor antagonist and β2 adrenoceptor agonist [MABA]) in a single molecule.
- Trial name
- NCT03159442
- Testing
- AZD8871
- Where
- United Kingdom
- Volunteers
- 25 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Healthy, COPD
A Multiple Ascending Dose Study With AZD9164 Given for 13 Days in Healthy Male and Female Subjects and in Patients With Chronic Obstructive Pulmonary Disease
The purpose of this study is to investigate the safety, tolerability, pharmacokinetics and pharmacodynamics of inhaled AZD9164 following administration of multiple ascending doses in healthy male and female subjects and COPD…
- Trial name
- NCT01016951
- Testing
- AZD9164 Turbuhaler®
- Where
- 2 sites in Sweden
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Pulmonary Disease, Chronic Obstructive
Ba253BINEB Compared to Ba253MDI (Metered Dose Inhaler) in Patients With Chronic Obstructive Pulmonary Disease (COPD)
The objective of this study is to investigate the efficacy and safety of Ba253BINEB during the continuous 4 weeks administration to the patients with COPD using Ba253MDI (Tersigan® aerosol) as the comparator drug.
- Trial name
- NCT02182583
- Testing
- Ba253MDI, Ba253BINEB
- Volunteers
- 163 people
- Sponsor
- Boehringer Ingelheim
Chronic Obstructive Pulmonary Disease
REported Outcomes in COPD With Trixeo in Real worlD
Chronic obstructive pulmonary disease (COPD) is characterized by persistent respiratory symptoms (including breathlessness, cough, and sputum production), which has a substantial impact on health-related quality of life (HRQoL).
- Trial name
- RECORD (NCT05213611)
- Where
- 31 sites in United Kingdom
- Volunteers
- 150 people
- Sponsor
- AstraZeneca
Pulmonary Disease, Chronic Obstructive
Predictive Ability of the Chronic Obstructive Pulmonary Disease (COPD) Assessment Test (CAT) for Acute Exacerbations (PACE) in Patients With COPD
Chronic Obstructive Pulmonary Disease (COPD) is a major health concern, with a substantial impact on a patient's life. However, the impact of COPD is currently under-recognised and, as a result, COPD is under-treated.
- Trial name
- PACE (NCT01254032)
- Where
- 19 sites in Australia, China and 2 more
- Volunteers
- 70 people
- Sponsor
- GlaxoSmithKline
Chronic Obstructive Pulmonary Disease (COPD)
Innovative Pulmonary Solutions (IPS) System for Targeted Lung Denervation
The purpose of this study is to evaluate the safety of Targeted Lung Denervation Therapy (or TLD TherapyTM) in patients suffering from COPD.
- Trial name
- IPS-I (NCT01483534)
- Testing
- TLD Therapy (IPS SystemTM)
- Where
- 3 sites in Netherlands, South Africa
- Volunteers
- 22 people
- Sponsor
- Nuvaira, Inc.
Pulmonary Disease, Chronic Obstructive
Study To Evaluate Safety And Tolerability Of GSK256066 In Chronic Obstructive Pulmonary Disease (COPD) Patients
This study will evaluate the safety and tolerability of the cfor the first time in mild to moderate COPD patients.
- Trial name
- NCT00549679
- Testing
- GSK256066
- Where
- 15 sites in Estonia, Finland and 4 more
- Volunteers
- 104 people
- Sponsor
- GlaxoSmithKline
Asthma, COPD
Switch of Budesonide-formoterol Dry Powder Inhalers at Pharmacy in Norway
This is a retrospective, multicentre, non-interventional, observational study in patients with asthma and/or COPD who are treated with budesonide-formoterol.
- Trial name
- BufoSwitch (NCT04663386)
- Testing
- Budesonide-Formoterol
- Where
- Norway
- Volunteers
- 29 people
- Sponsor
- Orion Corporation, Orion Pharma
Respiratory System Disease, Chronic Obstructive Pulmonary Disease
The Study for Evaluating the Clinical Effectiveness and Safety of Respiratory Rehabilitation Software 'Redpill Breath'(COPD, Asthma, Lung Cancer, Etc.)
The purpose of the study is to prove the clinical superiority of respiratory rehabilitation software "Redpill Breath" and evaluate the clinical improvement effect by 6-minute walk test of the software, compared to the manual…
- Conditions
- Respiratory System Disease, Chronic Obstructive Pulmonary Disease, Asthma Copd, Lung Cancer
- Trial name
- NCT05299385
- Testing
- Conventional rehabilition treatment(e.g leaflet) educated by hospital, Digital treatment based on Respiratory Rehabilitation Software
- Where
- 3 sites in South Korea
- Volunteers
- 100 people
- Sponsor
- Lifesemantics Corp.
Chronic Obstructive Pulmonary Disease (COPD)
Safety and Tolerability of QVA149 (Indacaterol/Glycopyrrolate) Compared to Placebo and to Indacaterol in Patients With Moderate to Severe Stable Chronic Obstructive Pulmonary Disease (COPD)
An investigational inhalation product (QVA149) for the treatment of patients with Chronic Obstructive Pulmonary Disease (COPD) is being developed.
- Trial name
- NCT00558285
- Testing
- indacaterol/glycopyrrolate, indacaterol, glycopyrrolate
- Where
- 40 sites in Australia, Belgium and 6 more
- Volunteers
- 257 people
- Sponsor
- Novartis
Chronic Obstructive Pulmonary Disease (COPD)
A Study to Investigate Efficacy and Safety of Tozorakimab Injections Compared With Placebo in Adult Participants With Symptomatic Chronic Obstructive Pulmonary Disease (COPD) With a History of COPD Exacerbations and Elevated Eosinophils
The purpose of this study is to investigate lung function parameters, composite endpoint for exacerbations in chronic obstructive pulmonary disease (COPDCompEx), symptoms and to provide safety information after tozorakimab or…
- Trial name
- COMETA (NCT06897748)
- Testing
- Tozorakimab
- Where
- 12 sites in Russia
- Volunteers
- 98 people
- Sponsor
- AstraZeneca
Chronic Obstructive Pulmonary Disease
Efficacy and Safety of Four Doses of Glycopyrronium Bromide (NVA237) in Patients With Stable Chronic Obstructive Pulmonary Disease (COPD), in Comparison to an Active Comparator Tiotropium
This study will assess the efficacy and safety of glycopyrronium bromide (NVA237) in patients with stable COPD, in comparison to an active comparator.
- Trial name
- NCT00501852
- Testing
- NVA237, Tiotropium
- Where
- 3 sites in Belgium, France and 1 more
- Volunteers
- 83 people
- Sponsor
- Novartis Pharmaceuticals
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.